BW

PPAR-γ (C-terminus) monoclonal Antibody | MB0080

(No reviews yet) Write a Review
SKU:
BW-MB0080
Availability:
Usually ships in 5 working days
£888.00 - £1,356.00

Description

PPAR-γ (C-terminus) monoclonal Antibody | MB0080 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Application: WB

Application Range: WB: 1:500

Background: PPAR gamma is implicated in numerous diseases including obesity, diabetes, atherosclerosis and cancer. PPAR gamma activators include prostanoids, fatty acids, thiazolidinediones and N- (2-benzoylphenyl) tyrosine analogues. A key component in adipocyte differentiation and fat-specific gene expression, PPAR gamma may modulate macrophage functions such as proinflammatory activities, and stimulate oxidized low-density lipoprotein (x-LDL) uptake. A Pro12Ala polymorphism of the PPAR gamma2 gene has been reported to reduce transactivation activity in vitro. This substitution may affect the immune response to ox-LDL and be associated with type 2 diabetes. In addition, the Pro12Ala variant of the PPAR gamma2 gene maybe correlated with abdominal obesity in type 2 diabetes.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: This Antibody detects endogenous levels of PPAR gamma (C-terminus) and does not cross-react with related proteins

Molecular Weight: ~53/57kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: CIMT1; GLM1; NR1C3; Nuclear receptor subfamily 1 group C member 3; OTTHUMP00000185032; OTTHUMP00000185036; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Acti

Immunogen: Synthetic peptide, corresponding to amino acids C-terminus of Human PPAR-γ.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from mouse ascites by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway:

View AllClose